|
|
Marketing Authorisations
|
|
|
|
|
An alternative to surgery but with the risks of a cytotoxic drug, teratogenic in the case of short delay before conception
|
|
|
|
|
|
|
|
|
|
Encouraging results in first-line treatment need to be confirmed
|
|
|
|
|
|
|
|
|
|
Unfavourable harm-benefit balance
|
|
|
|
|
|
Adverse Effects
|
|
|
|
|
Sometimes a sign of overdose or withdrawal
|
|
|
|
|
|
Reviews
|
|
|
|
|
Uncertain benefits, established harms
|
|
|
|
|
|
|
|
|
|
Risks from combining two immunostimulants
|
|
|
|
|
|
|
|
|
|
Immediate treatment, or not: 10-year results
|
|
|
|
Outlook
|
|
|
|
|
An opportunity to discuss the dangers of drugs during pregnancy
|
|
|
|
|
|
|
|
|
|
|
|
Increased threat to patient safety
|
|
|
|
|
|